◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

SinoMab BioScience Limited (3681) Financial History

Name: SinoMab BioScience Limited (3681) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-08-10

SinoMab BioScience Limited (3681) operates in the Biotechnology industry and is headquartered in Tai Po, Hong Kong with about 95 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 3681 reported CNY 0M in revenue and (CNY 105M) in net income.

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong.

Interactive charts & full statements →

3681 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 0M	CNY 2M	CNY 1M	CNY 0M
Gross Profit	CNY 0M	CNY 0M	CNY 0M	CNY 0M
Operating Income (EBIT)	(CNY 123M)	(CNY 161M)	(CNY 230M)	(CNY 259M)
Net Income	(CNY 105M)	(CNY 185M)	(CNY 243M)	(CNY 284M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

3681 Free Cash Flow History

3681 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Total Assets	CNY 908M	CNY 753M	CNY 848M	CNY 1.0B	—
Total Liabilities	CNY 400M	CNY 560M	CNY 552M	CNY 499M	—

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 3681 viewer.

Other Companies in Biotechnology

TSHA · Taysha Gene Therapies, Inc. — $2 billion
DMRA · Damora Therapeutics, Inc. — $2 billion
AGIO · Agios Pharmaceuticals, Inc. — $2 billion
OCUL · Ocular Therapeutix, Inc. — $2 billion
GENB · Generate Biomedicines, Inc. — $2 billion
KARD · Kardigan, Inc. — $2 billion
SNDX · Syndax Pharmaceuticals, Inc. — $2 billion
RXRX · Recursion Pharmaceuticals, Inc. — $2 billion

← 3680 All “0-9” companies 3682 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.